Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock Rated “Moderate Buy” by Wall Street Brokerages

Shares of Odyssey Therapeutics, Inc. (NASDAQ:ODTX) have been assigned a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $37.00.

Several equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. raised their price target on shares of Odyssey Therapeutics from $26.00 to $29.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Raymond James Financial initiated coverage on Odyssey Therapeutics in a report on Thursday. They set an “outperform” rating and a $42.00 target price on the stock. Wall Street Zen lowered Odyssey Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 20th. Oppenheimer reiterated an “outperform” rating and issued a $40.00 price target on shares of Odyssey Therapeutics in a research report on Thursday, June 18th. Finally, Weiss Ratings started coverage on Odyssey Therapeutics in a research note on Tuesday, August 11th. They issued a “sell (d+)” rating for the company.

Institutional Trading of Odyssey Therapeutics

Several institutional investors have recently added to or reduced their stakes in ODTX. State Street Corp bought a new position in Odyssey Therapeutics during the 2nd quarter worth approximately $1,477,000. The Manufacturers Life Insurance Company acquired a new position in shares of Odyssey Therapeutics in the 2nd quarter worth approximately $601,000. Finally, Citadel Advisors LLC acquired a new position in shares of Odyssey Therapeutics in the 2nd quarter worth approximately $4,162,000.

Odyssey Therapeutics Stock Performance

NASDAQ:ODTX opened at $19.00 on Monday. The stock’s 50 day simple moving average is $22.76. Odyssey Therapeutics has a one year low of $15.10 and a one year high of $29.05. The firm has a market cap of $913.12 million and a P/E ratio of -2.81.

Odyssey Therapeutics (NASDAQ:ODTX) last posted its earnings results on Wednesday, August 5th. The company reported ($1.74) earnings per share for the quarter. On average, equities analysts predict that Odyssey Therapeutics will post -6.20 earnings per share for the current fiscal year.

Odyssey Therapeutics Company Profile

Odyssey Therapeutics is a biotechnology company focused on discovering and developing precision medicines for serious diseases, with an emphasis on immunology and oncology. The company uses a combination of human genetics, functional genomics, computational biology, machine learning and medicinal chemistry to identify disease targets and advance potential therapeutic programs.

Odyssey’s research and development activities are centered on small-molecule medicines designed to address genetically validated targets and specific disease mechanisms.